Identification of a novel aberrant spliceosome of MPL gene (MPLL391-V392ins12)in patients with myeloproliferative neoplasms.
- Author:
Ruiyuan TIAN
1
;
Xiuhua CHEN
1
;
Jianmei CHANG
1
;
Na ZHANG
1
;
Yanhong TAN
1
;
Zhifang XU
1
;
Fanggang REN
1
;
Junxia ZHAO
1
;
Jie PAN
1
;
Haixiu GUO
1
;
Xiaojuan WANG
1
;
Hongwei WANG
1
Author Information
- Publication Type:Journal Article
- MeSH: Humans; Mutation; Myeloproliferative Disorders; genetics; Neoplasms; genetics; Polymerase Chain Reaction; Receptors, Thrombopoietin; genetics; Spliceosomes
- From: Chinese Journal of Hematology 2015;36(7):559-562
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo identify the MPL L391-V392ins12 spliceosome and analyze its frequencies in patients with myeloproliferative neoplasms (MPN).
METHODSMPL aberrant spliceosome was identified through reverse transcription polymerase chain reaction (RT-PCR)combined with cloning sequencing. The mutation of this spliceosome in 248 MPN patients and 200 normal people was determined by allele-specific polymerase chain reaction (AS-PCR).
RESULTSA novel aberrant spliceosome of MPL gene (MPL L391-V392ins12)was identified, i.e. 36 bp intron was retained between exon7 and exon8, and there were 12 amino acids (EGLKLLPADIPV)inserted. MPL L391-V392ins12 mutation was detected in 19 (7.66%)of the 248 patients with MPN, including 1 (1.92%) of 52 patients with PV, 14 (9.66%) of 145 with ET, and 4 (7.84%) of 51 with PMF. And the mutation was not detected in the group of 200 normal people.
CONCLUSIONMPL L391-V392ins12 spliceosome is an aberrant spliceosome present in the MPN. It can be detected in PV, ET and PMF, and more frequently in ET and PMF. This mutation may play an important role in the process of MPN.
